Top of page Skip navigation

Advisory Board


Jane Dancer

Jane joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in  Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.


Hakan Goker 

Hakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture, investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Synaffix BV and is acting CBO of Asceneuron SA.


Flic Gabbay

Founder/Partner, TranScrip Flic is Managing Partner of TranScrip of which she was a co-founder in 2008 and has worked in the pharmaceutical industry for more than 30 years. She has held senior positions in pharma and bio-tech companies in Europe and North America and worked on a range of products including small molecules and biologicals. She has been involved in registration programmes in US and Europe and launches of antibiotics, antifungals, respiratory, anti-inflammatories, lipid lowering agents, and anticancer including five she has worked on and defended within TranScrip. Previously Flic was a Regional Director of clinical research for Parke Davis and Head of Anti-infectives and she founded Gabbay Group, a CRO acquired by PPD where she became Global VP for Regulatory and Clinical Research. She was Founding Chairman of Phico Therapeutics and has also been CEO of two small biotech companies, Director of Education at the Drug Safety Research Unit in Southampton and Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and, for nine years, was its Academic Registrar.



Alan Palmer


Alan Palmer is an internationally recognised neuroscientist and a serial entrepreneur, whose career has focussed on neurodegenerative disorders and their treatment. Currently, he is (i) a Board member of Cerebroscience Ltd, MS Therapeutics Ltd (MST), the British Neuroscience Association and One Nucleus Ltd; (ii) a visiting Professor at both University College London and the University of Reading; (iii) Life Science Entrepreneur in Residence at the University of Bristol; (iv) a Fellow of the Society of Biology; and (iv) a member of the Scientific Advisory Board of both GE Healthcare Medical Diagnostics Ltd and Pharmidex Pharmaceutical Services Ltd (Pharmidex). Alan has over 100 peer-reviewed papers to his name, 36 of which are highly cited (> 50 citations); total number of citations > 6,000. Formerly, Alan was: (i) voted London Biotechnology Network Entrepreneur of the Year; (ii) Chairman of the Society for Medicines Research;. (iii) a member of the UK Government’s Biotech Pharma Sector Advisory Group; (iv) Group Leader, Wyeth Research Ltd; (v) Principal Investigator, Alzheimer’s Disease Research Centre, University of Pittsburgh Medical School (UPMC); and (vi). Principal Investigator, Head Injury Research Centre, UPMC. He has founded or co-founded a number of companies, including Cerebroscience, MST, New Medicines Discovery, Pharmidex, Cerexus, and Cerebrus (now Vernalis). 


Sir Keith Peters

From 1977 to 1987 Keith Peters was Professor and Director of the Department of Medicine at the Royal Postgraduate Medical School at Hammersmith Hospital and from 1987-2005 Regius Professor of Physic and the Head of the Clinical School at the University of Cambridge. His research has been on elucidation of immunological mechanisms underlying diseases of kidney and blood vessels, and this has led to new treatments – in particular the introduction of plasma exchange and immunosuppression - for these diseases. Cambridge, under his leadership, has become a major centre for clinical research, complementing the University’s longstanding strengths in basic biomedical science. He was a founder Fellow of the Academy of Medical Sciences and its second President. From 2006-2008 he was Interim Director of the MRC’s National Institute for Medical Research and initiated discussions which led to the establishment of the UK Centre for Medical Research and Innovation , the Francis Crick Institute . The Institute – which is now being built at St Pancras - is a partnership between the MRC, CRUK, The Wellcome Trust, and UCL, KCL and Imperial College. He has been involved in Singapore medicine in various ways, including advisory roles on Biopolis, the A Star Graduate Academy and the NUS-Duke Graduate Medical School. For the past 10 years he has been a Senior Consultant in R&D at GSK. He was Knighted in 1993 and elected Fellow of the Royal Society in 1995. 


Rob Pinnock

Rob joined MSD’s licensing team in Sept 2007 and since mid 2008 his remit is to identify partnering opportunities in the UK, Ireland, Portugal & Spain.

Before joining MSD Rob worked for a year in Cambridge University on neuronal injury & prosthetics. He spent time in Biotech between 2004-6, advancing programs in CV, metabolic disease & pain from concept to clinic. Previously he held positions of increasing seniority in Parke Davis,Cambridge,UK, until their acquisition by Pfizer.  In 2001 he moved to Pfizer research laboratories inAnn Arbor,Michigan, as senior director for CNS Molecular Science. Collaborations were an important part of Rob’s mandate at Parke-Davis / Pfizer.  Before he joined the pharmaceutical industry Rob trained in Southampton & spent several years as a research fellow at the MRC andUniversityofCambridge. 



David Tapolczay

Dr David Tapolczay has 28 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition David was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium David was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT).

David has an international reputation in the pharmaceutical industry as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. In addition he is a non executive director for several biotech companies.


Media Partner


Partnering powered by